Corvus Pharmaceuticals, Inc.
(NASDAQ : CRVS)

( )
CRVS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.01%167.590.7%$1123.19m
PFEPfizer Inc. -1.18%49.270.9%$913.61m
LLYEli Lilly & Co. 2.11%316.851.1%$810.94m
ABBVAbbVie, Inc. -0.77%141.451.9%$792.28m
MRKMerck & Co., Inc. 0.46%91.010.7%$787.57m
BMYBristol-Myers Squibb Co. 0.57%74.551.0%$638.52m
SIGASIGA Technologies, Inc. 1.85%24.770.0%$466.92m
AZNAstraZeneca Plc -0.48%66.421.0%$364.06m
GBTGlobal Blood Therapeutics, Inc. 0.00%67.005.6%$344.80m
GSKGSK Plc -1.65%34.680.3%$292.03m
ALNYAlnylam Pharmaceuticals, Inc. -2.20%223.138.2%$270.05m
VERUVeru, Inc. 6.88%23.780.0%$243.99m
HZNPHorizon Therapeutics Plc -3.67%61.735.4%$222.09m
CCXIChemoCentryx, Inc. -0.16%50.782.9%$208.38m
KRTXKaruna Therapeutics, Inc. -0.93%261.230.0%$204.24m

Company Profile

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.